Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stevens-Johnson Syndrome | 9 | 2021 | 249 | 4.400 |
Why?
|
Psoriasis | 15 | 2022 | 939 | 4.270 |
Why?
|
Skin Diseases | 8 | 2021 | 1113 | 2.600 |
Why?
|
Skin Diseases, Vesiculobullous | 2 | 2022 | 88 | 1.800 |
Why?
|
Sarcoidosis | 4 | 2020 | 504 | 1.630 |
Why?
|
Dermatology | 6 | 2021 | 802 | 1.340 |
Why?
|
Drug Prescriptions | 4 | 2021 | 1683 | 0.900 |
Why?
|
Dermatologic Agents | 3 | 2020 | 309 | 0.820 |
Why?
|
Ultraviolet Therapy | 1 | 2019 | 84 | 0.760 |
Why?
|
Vaccination | 3 | 2021 | 2487 | 0.750 |
Why?
|
Granuloma | 2 | 2017 | 331 | 0.720 |
Why?
|
Severity of Illness Index | 11 | 2020 | 16227 | 0.700 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2017 | 237 | 0.630 |
Why?
|
Immunocompromised Host | 1 | 2021 | 889 | 0.600 |
Why?
|
Biological Products | 3 | 2019 | 718 | 0.590 |
Why?
|
Pharmacoepidemiology | 1 | 2018 | 292 | 0.570 |
Why?
|
Skin | 4 | 2022 | 4456 | 0.570 |
Why?
|
Cyclosporine | 1 | 2018 | 856 | 0.560 |
Why?
|
Immunosuppressive Agents | 3 | 2021 | 4208 | 0.510 |
Why?
|
Pemphigoid, Bullous | 2 | 2010 | 77 | 0.490 |
Why?
|
Influenza Vaccines | 1 | 2018 | 602 | 0.490 |
Why?
|
Drug Utilization | 1 | 2019 | 1248 | 0.480 |
Why?
|
Anti-Inflammatory Agents | 2 | 2019 | 1794 | 0.470 |
Why?
|
Mycosis Fungoides | 1 | 2013 | 150 | 0.460 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2013 | 193 | 0.440 |
Why?
|
Pemphigoid Gestationis | 1 | 2010 | 2 | 0.430 |
Why?
|
Collagen Type VII | 1 | 2008 | 15 | 0.390 |
Why?
|
Epidermolysis Bullosa Acquisita | 1 | 2008 | 15 | 0.390 |
Why?
|
Trophoblasts | 1 | 2010 | 221 | 0.370 |
Why?
|
Hospital Mortality | 2 | 2021 | 5065 | 0.360 |
Why?
|
Analgesics, Opioid | 3 | 2021 | 3037 | 0.360 |
Why?
|
Mohs Surgery | 2 | 2021 | 170 | 0.360 |
Why?
|
Influenza, Human | 1 | 2018 | 1271 | 0.360 |
Why?
|
Arthritis, Psoriatic | 3 | 2021 | 249 | 0.340 |
Why?
|
Hepatitis C | 1 | 2017 | 1475 | 0.340 |
Why?
|
Paraproteinemias | 2 | 2020 | 216 | 0.330 |
Why?
|
Autoantibodies | 3 | 2010 | 1925 | 0.310 |
Why?
|
Models, Theoretical | 1 | 2019 | 3621 | 0.310 |
Why?
|
Chronic Disease | 4 | 2022 | 8882 | 0.300 |
Why?
|
Middle Aged | 30 | 2022 | 216468 | 0.280 |
Why?
|
Humans | 47 | 2022 | 686663 | 0.260 |
Why?
|
Electronic Health Records | 5 | 2020 | 3836 | 0.260 |
Why?
|
Adult | 24 | 2022 | 211400 | 0.260 |
Why?
|
United States | 12 | 2022 | 65579 | 0.240 |
Why?
|
Acute Generalized Exanthematous Pustulosis | 1 | 2022 | 12 | 0.240 |
Why?
|
Female | 32 | 2022 | 375459 | 0.240 |
Why?
|
Quality of Life | 2 | 2021 | 10676 | 0.240 |
Why?
|
Placenta | 1 | 2010 | 1353 | 0.230 |
Why?
|
Skin Neoplasms | 3 | 2019 | 5354 | 0.230 |
Why?
|
Biomedical Research | 1 | 2018 | 3285 | 0.230 |
Why?
|
Liver | 1 | 2017 | 7653 | 0.210 |
Why?
|
Male | 30 | 2021 | 352465 | 0.210 |
Why?
|
Necrobiotic Xanthogranuloma | 1 | 2020 | 12 | 0.210 |
Why?
|
Transdermal Patch | 1 | 2020 | 42 | 0.210 |
Why?
|
Non-Fibrillar Collagens | 2 | 2010 | 23 | 0.210 |
Why?
|
Retrospective Studies | 16 | 2022 | 67320 | 0.210 |
Why?
|
Perforin | 1 | 2020 | 174 | 0.200 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2013 | 4355 | 0.200 |
Why?
|
Fas Ligand Protein | 1 | 2020 | 230 | 0.200 |
Why?
|
Necrobiosis Lipoidica | 1 | 2019 | 11 | 0.200 |
Why?
|
Risk Assessment | 3 | 2019 | 23739 | 0.200 |
Why?
|
Sulfamethoxazole | 1 | 2018 | 50 | 0.190 |
Why?
|
Trimethoprim | 1 | 2018 | 92 | 0.190 |
Why?
|
Immune System Diseases | 1 | 2020 | 260 | 0.180 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2020 | 1039 | 0.170 |
Why?
|
Sweet Syndrome | 1 | 2017 | 56 | 0.170 |
Why?
|
Hidradenitis Suppurativa | 1 | 2019 | 125 | 0.170 |
Why?
|
Pyoderma Gangrenosum | 1 | 2018 | 68 | 0.170 |
Why?
|
Whole Body Imaging | 1 | 2019 | 274 | 0.160 |
Why?
|
Phototherapy | 1 | 2020 | 338 | 0.160 |
Why?
|
Aged | 17 | 2021 | 162271 | 0.160 |
Why?
|
Patient Acceptance of Health Care | 2 | 2021 | 2912 | 0.160 |
Why?
|
Population Surveillance | 2 | 2017 | 2693 | 0.150 |
Why?
|
Nevus, Sebaceous of Jadassohn | 1 | 2015 | 3 | 0.150 |
Why?
|
Cellulitis | 1 | 2018 | 204 | 0.150 |
Why?
|
Keratinocytes | 1 | 2020 | 834 | 0.150 |
Why?
|
Autoantigens | 2 | 2010 | 914 | 0.140 |
Why?
|
Cohort Studies | 6 | 2020 | 38732 | 0.140 |
Why?
|
Withholding Treatment | 1 | 2019 | 600 | 0.140 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2015 | 83 | 0.140 |
Why?
|
Arthritis, Rheumatoid | 3 | 2018 | 3492 | 0.140 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1812 | 0.130 |
Why?
|
Sweat Gland Neoplasms | 1 | 2015 | 112 | 0.130 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2018 | 627 | 0.130 |
Why?
|
Physician's Role | 1 | 2021 | 995 | 0.130 |
Why?
|
Comorbidity | 4 | 2022 | 10648 | 0.130 |
Why?
|
Incidental Findings | 1 | 2019 | 699 | 0.130 |
Why?
|
Immunoglobulin E | 2 | 2010 | 1448 | 0.130 |
Why?
|
Anti-Infective Agents | 1 | 2020 | 924 | 0.130 |
Why?
|
Arthritis | 1 | 2018 | 637 | 0.120 |
Why?
|
Prognosis | 3 | 2019 | 28923 | 0.120 |
Why?
|
Blood Vessels | 1 | 2019 | 1214 | 0.120 |
Why?
|
Th17 Cells | 1 | 2019 | 705 | 0.120 |
Why?
|
Risk Factors | 7 | 2021 | 69278 | 0.120 |
Why?
|
Scalp | 1 | 2015 | 348 | 0.120 |
Why?
|
Morbidity | 1 | 2018 | 1674 | 0.120 |
Why?
|
Survival Rate | 2 | 2018 | 13606 | 0.120 |
Why?
|
Cross-Sectional Studies | 7 | 2021 | 21640 | 0.120 |
Why?
|
Adrenal Cortex Hormones | 2 | 2018 | 1809 | 0.120 |
Why?
|
Administration, Oral | 1 | 2020 | 3975 | 0.110 |
Why?
|
Prevalence | 4 | 2019 | 14744 | 0.110 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 4076 | 0.110 |
Why?
|
Acute Disease | 1 | 2022 | 7202 | 0.110 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2191 | 0.110 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2015 | 656 | 0.110 |
Why?
|
Neoplasms | 4 | 2020 | 19538 | 0.110 |
Why?
|
Patient Education as Topic | 1 | 2021 | 2371 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2020 | 1477 | 0.100 |
Why?
|
Anticonvulsants | 1 | 2020 | 1875 | 0.100 |
Why?
|
Liver Diseases | 1 | 2017 | 1224 | 0.100 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2256 | 0.100 |
Why?
|
Survivors | 1 | 2020 | 2033 | 0.100 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2008 | 81 | 0.100 |
Why?
|
Incidence | 5 | 2018 | 20496 | 0.090 |
Why?
|
Microscopy, Immunoelectron | 1 | 2008 | 348 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2020 | 4477 | 0.090 |
Why?
|
Young Adult | 6 | 2020 | 56052 | 0.090 |
Why?
|
Feasibility Studies | 1 | 2017 | 4807 | 0.090 |
Why?
|
Inpatients | 1 | 2018 | 2050 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2018 | 1429 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 2018 | 2092 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4115 | 0.080 |
Why?
|
Aged, 80 and over | 5 | 2019 | 59331 | 0.080 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3449 | 0.080 |
Why?
|
Antibody Formation | 1 | 2010 | 1416 | 0.080 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15407 | 0.080 |
Why?
|
Disease Management | 1 | 2017 | 2586 | 0.070 |
Why?
|
Communication | 1 | 2019 | 3237 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2018 | 3296 | 0.070 |
Why?
|
Biopsy | 1 | 2017 | 6849 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 11616 | 0.070 |
Why?
|
Pilot Projects | 1 | 2017 | 7791 | 0.070 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2018 | 2155 | 0.070 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2017 | 3454 | 0.060 |
Why?
|
Imaging, Three-Dimensional | 1 | 2017 | 4054 | 0.060 |
Why?
|
Epitopes | 1 | 2010 | 2716 | 0.060 |
Why?
|
Apoptosis | 1 | 2020 | 10261 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2017 | 3027 | 0.060 |
Why?
|
Sex Factors | 1 | 2017 | 10926 | 0.060 |
Why?
|
Inflammation | 2 | 2019 | 9617 | 0.060 |
Why?
|
Adolescent | 6 | 2022 | 84957 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 4958 | 0.060 |
Why?
|
Research Design | 1 | 2018 | 5835 | 0.060 |
Why?
|
Hospitalization | 1 | 2021 | 9304 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2017 | 19308 | 0.050 |
Why?
|
Time Factors | 3 | 2019 | 42271 | 0.050 |
Why?
|
Vaccines, Attenuated | 1 | 2021 | 326 | 0.050 |
Why?
|
Opiate Alkaloids | 1 | 2019 | 15 | 0.050 |
Why?
|
Prospective Studies | 3 | 2020 | 49071 | 0.050 |
Why?
|
Mental Disorders | 1 | 2019 | 6378 | 0.050 |
Why?
|
Iowa | 1 | 2019 | 103 | 0.050 |
Why?
|
Potassium Iodide | 1 | 2017 | 13 | 0.050 |
Why?
|
Interleukin-23 | 1 | 2019 | 183 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17071 | 0.040 |
Why?
|
Folic Acid Antagonists | 1 | 2017 | 76 | 0.040 |
Why?
|
Dapsone | 1 | 2017 | 62 | 0.040 |
Why?
|
Filgrastim | 1 | 2017 | 142 | 0.040 |
Why?
|
Leukopenia | 1 | 2017 | 213 | 0.040 |
Why?
|
Hematologic Agents | 1 | 2017 | 42 | 0.040 |
Why?
|
Body Surface Area | 1 | 2017 | 211 | 0.040 |
Why?
|
Tubulin Modulators | 1 | 2017 | 118 | 0.040 |
Why?
|
Spondylitis, Ankylosing | 1 | 2018 | 137 | 0.040 |
Why?
|
Polycythemia Vera | 1 | 2018 | 139 | 0.040 |
Why?
|
Colchicine | 1 | 2017 | 254 | 0.040 |
Why?
|
Interleukin-12 | 1 | 2019 | 601 | 0.040 |
Why?
|
Obesity | 1 | 2019 | 11700 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2019 | 15083 | 0.040 |
Why?
|
Thyroid Diseases | 1 | 2019 | 369 | 0.040 |
Why?
|
Asymptomatic Diseases | 1 | 2019 | 572 | 0.040 |
Why?
|
Botswana | 1 | 2018 | 942 | 0.040 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2015 | 25 | 0.040 |
Why?
|
Cystadenoma | 1 | 2015 | 88 | 0.040 |
Why?
|
Fluorine Radioisotopes | 1 | 2019 | 474 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2017 | 10088 | 0.040 |
Why?
|
Placebos | 1 | 2019 | 1791 | 0.030 |
Why?
|
Outpatients | 1 | 2021 | 1248 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2019 | 1950 | 0.030 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2017 | 464 | 0.030 |
Why?
|
Postoperative Period | 1 | 2019 | 1861 | 0.030 |
Why?
|
Arthralgia | 1 | 2017 | 439 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2010 | 20620 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2436 | 0.030 |
Why?
|
Age Distribution | 1 | 2019 | 2963 | 0.030 |
Why?
|
Consensus | 1 | 2021 | 2434 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2018 | 836 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2022 | 2100 | 0.030 |
Why?
|
Research | 1 | 2021 | 2061 | 0.030 |
Why?
|
Dyslipidemias | 1 | 2019 | 815 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2017 | 1127 | 0.030 |
Why?
|
Perioperative Care | 1 | 2019 | 1076 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2019 | 1983 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2019 | 1971 | 0.020 |
Why?
|
Pregnancy | 1 | 2010 | 25703 | 0.020 |
Why?
|
Anemia | 1 | 2017 | 1357 | 0.020 |
Why?
|
Child | 3 | 2021 | 71361 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2019 | 2697 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2777 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39737 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2017 | 21684 | 0.020 |
Why?
|
Critical Care | 1 | 2018 | 2413 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2019 | 11866 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10766 | 0.020 |
Why?
|
Cytokines | 1 | 2019 | 7147 | 0.020 |
Why?
|
Databases, Factual | 1 | 2019 | 7865 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2022 | 6829 | 0.020 |
Why?
|
Disease Progression | 1 | 2020 | 13204 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2020 | 4844 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8070 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2017 | 6009 | 0.010 |
Why?
|
Smoking | 1 | 2019 | 9029 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2009 | 2923 | 0.010 |
Why?
|
Blotting, Western | 1 | 2009 | 5678 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 19295 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2019 | 23953 | 0.010 |
Why?
|
Hypertension | 1 | 2019 | 7941 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 13603 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2019 | 60991 | 0.010 |
Why?
|
Infant | 1 | 2019 | 33918 | 0.010 |
Why?
|
Child, Preschool | 1 | 2019 | 41159 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 15075 | 0.010 |
Why?
|
Mutation | 1 | 2017 | 28848 | 0.010 |
Why?
|
Concepts
(221)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(16)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_